Please login to the form below

Highly Specialised Technology

This page shows the latest Highly Specialised Technology news and features for those working in and with pharma, biotech and healthcare.

NICE approves BioMarin’s Brineura after initial setback

The positive recommendation of Brineura was agreed by NICE’s Highly Specialised Technology committee. ... Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE.

Latest news

Spinraza managed access deal in England breaks deadlock for Biogen

a prevalence to go through NICE's highly specialised technology (HST) route, which is reserved for the rarest orphan and ultra-orphan treatments. ... Patient groups say the health economics of a rare disease like SMA make it highly unlikely to be passed
NICE knocks back BioMarin’s Batten disease drug

The decision, which was published under NICE’s Highly Specialised Technology (HST) committee, marks the end of a year-long negotiation between BioMarin and NHS England. ... Once these elements are excluded, the cost-effectiveness estimates for
‘Inflexible’ NICE blocking access to rare disease drugs

NICE has a Highly Specialised Technology (HST) appraisal, which has seen a number of innovative pricing and reimbursement deals done with companies to bring orphan and ultra-orphan drugs to NHS ... patients. However many rare diseases do not qualify for
NICE appraisal fees to be introduced despite opposition

The fee for single technology appraisals (STAs) and highly specialised technology appraisals (HTAs) will be £126, 000 ($158, 500, 140, 400).
Promising more appraisal capacity, NICE revives industry fee idea

NICE is proposing that bigger companies pay £126, 000 ($160, 000) for a single technology appraisal or a highly specialised technology appraisal (for rare disease drugs), or £94, 500 for smaller ... Industry association the ABPI hasn’t yet responded

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Evolution or revolution: the latest review of NICE methods

The 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) included a commitment from NICE to scope and initiate a review of the methods for its Technology Appraisal Programme (TAP) ... A broad range of technologies. NICE has said that the
#OrkambiNow?

The row boiled over into accusations being traded publicly – Vertex calling the health service budget holder’s stance ‘outrageous’ last summer and NHS England’s head of specialised medicines commissioning John ... The STA system doesn’t
Rare diseases: meeting the challenge

NICE, which has its own Highly Specialised Technology (HST) assessment process, has come under fire for the change in April 2017 to the way it assesses therapies to treat the rarest

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Account Director: Competitive

Healthcare Senior Account Manager: Competitive

Healthcare Lead Copywriter: Competitive

Medical Editor: Competitive

PMHub

Add my company

3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...